Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Newsletters and Deep Dive digital magazine
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.
CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
Leela Barham digs deeper into the progress update from NHS England in July 2026.
Editor's Picks
Newsletters and Deep Dive
digital magazine